Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV

Hypertension Clinical Trial

Official title:

Efficacy of Tamarindus Indica Fruit Juice in Optimizing Cardiometabolic Health of Patients Living With HIV and Elevated Triglycerides

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06058845
• Other study ID #: Tamarind_001
• Status: Completed
• Phase: N/A
• Start date: October 1, 2023
• Est. completion date: January 30, 2024

Study information

• Verified date: March 2024
• Source: KU Leuven
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The increasing burden of metabolic disturbances among People Living with HIV especially in developing countries has posed need for scientifically-proven, innovative, sustainable and cost-effective local adjuvant remedies to supplement conventional medical interventions. The goal of this clinical trial is to test the potential of Tamarindus indica fruit juice to improve cardiometabolic health of PLWH and elevated Triglycerides (TG). The main aims it aims to answer are to; - evaluate the efficacy of T. indica fruit juice on selected markers of lipid and glucose metabolism, and vascular health. - investigate a possible dose-response relationship on cardiometabolic control following intake of varying concentrations (fruit pulp percentages) of T. indica fruit juice. Participants will be required to consume 600 ml of either 10% or 30% fruit pulp juice a day for 30 days. From the baseline measurements, participants will be asked to comeback for repeat measurements after 14 days and finally on the 3oth day (Endline). Researchers will compare the groups that will be expose to the two juice prototypes to determine potential differences in TG levels.

Description:

Suboptimal cardiometabolic health is on a disproportional rise in Low- and Middle-Income Countries (LMICs). In sub-Saharan Africa (SSA), cardiometabolic dysfunction is being exacerbated by the ongoing nutrition transition, that has seen a change from traditional diets to fast and ultra processed foods rich in sugar, fats, and salt coupled by low physical activity (Kiyimba et al., 2022). Similarly, chronic inflammatory diseases such as HIV can aggravate cardiometabolic risks (Todowedo et al., 2019). Beyond conventional nutrients, fruits and vegetables have ubiquitous amounts of bioactive components including polyphenols, alkaloids, saponins, and terpenes and terpenoids, with polyphenols being the most ubiquitous of all. Dietary polyphenols are a diverse category of secondary plant metabolites that represent the largest group of naturally occurring antioxidants with cardioprotective benefits (Rijha et al., 2022 and Quero et al., 2020). Our recent inventory study of Uganda's IFV with purported cardiometabolic benefits, highlighted the popularity of Tamarindus indica as a local adjuvant therapy for cardiometabolic risks among Ugandan communities (Kiyimba et al., 2023). T. indica, is a leguminous tree belonging to the family Fabaceae with a wide range of bioactive constituents in varying levels- the highest being polyphenols followed by alkaloids, saponins, and terpenoids in that order (Luca et al., 2019 and Penev et al., 2016). Therefore, the aim of this trial is to evaluate the efficacy of T. indica fruit juice (added to patients' usual diets) on selected cardiometabolic risk markers of PLWH under the community-based HIV care model in Uganda in a proof-of-concept clinical trial. Two blinded juice prototypes of 10% and 30% fruit pulp packaged in amber bottles each consisting of 300mls will be supplied by the Uganda Natural Chemotherapeutics Research Institute. This is a single centre, 2-arm, 4 weeks randomised, double-blinded parallel trial with equal allocation ratios. The study participants will be randomly allocated to consume twice-daily 600 mL of either 10% or 30% pulp of T. indica fruit juice. Both participants and the study team will be blinded to the intervention materials. Measurements will be performed at three different timelines: Baseline, Week two of the study, and Endline (week four of the study). Compliance to the study protocol will be confirmed by weekly telephone inquiries, and by counting the returned empty juice bottles or unused study products at each follow-up visit. Participants will be asked to maintain their habitual dietary regimen. The two juice prototypes will be blinded by assigning a secret code to each of the intervention products. As such, blinding of the investigators and participants will be undertaken to ensure a double-blind intervention. Moreover, the statistical analyses of the main endpoints will be done before breaking the intervention product concealment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: January 30, 2024
• Est. primary completion date: January 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 60 Years

Eligibility

Inclusion Criteria:

• Triglycerides =150 mg/dL
• TLD regimen (ART) for =12 months
• 95% ART adherence in last 6 months
• Virally suppressed (most recent results viral load suppressed within the last 12 months)
• PLWH aged =30=60 years.
• No plans to change location in the next 6 months

Exclusion Criteria:

• Taking dietary supplements
• TB co-infection, renal failure disease, liver cirrhosis, chronic pancreatitis
• Pregnancy and Lactation or regular sport activity
• Parallel participation in another clinical trial
• On treatment for; dyslipidemia, hypertension or diabetes and oral hypoglycemic drugs
• Very low blood pressure (< 90/50 mmHg)
• Not willing to consent or unable to consent

Related Conditions & MeSH terms

• Cardiometabolic Syndrome
• Dyslipidemias
• Hypertension
• Metabolic Syndrome

Intervention

Dietary Supplement:
• Tamarindus indica fruit juice_A
The participants will be exposed to 10% Tamarind pulp juice
• Tamarindus indica fruit juice_B
The participants will be exposed to 30% Tamarind pulp juice

Locations

Country	Name	City	State
Uganda	Kajjansi HCIV	Wakiso

Sponsors (2)

Lead Sponsor	Collaborator
KU Leuven	Mildmay Uganda Limited

Country where clinical trial is conducted

Uganda, 

References & Publications (6)

Kiyimba T, Kigozi F, Yiga P, Mukasa B, Ogwok P, Van der Schueren B, Matthys C. The cardiometabolic profile and related dietary intake of Ugandans living with HIV and AIDS. Front Nutr. 2022 Aug 11;9:976744. doi: 10.3389/fnut.2022.976744. eCollection 2022. — View Citation

Luca SV, Macovei I, Bujor A, Miron A, Skalicka-Wozniak K, Aprotosoaie AC, Trifan A. Bioactivity of dietary polyphenols: The role of metabolites. Crit Rev Food Sci Nutr. 2020;60(4):626-659. doi: 10.1080/10408398.2018.1546669. Epub 2019 Jan 7. — View Citation

Penev L, Paton A, Nicolson N, Kirk P, Pyle RL, Whitton R, Georgiev T, Barker C, Hopkins C, Robert V, Biserkov J, Stoev P. A common registration-to-publication automated pipeline for nomenclatural acts for higher plants (International Plant Names Index, IPNI), fungi (Index Fungorum, MycoBank) and animals (ZooBank). Zookeys. 2016 Jan 7;(550):233-46. doi: 10.3897/zookeys.550.9551. eCollection 2016. — View Citation

Quero J, Marmol I, Cerrada E, Rodriguez-Yoldi MJ. Insight into the potential application of polyphenol-rich dietary intervention in degenerative disease management. Food Funct. 2020 Apr 30;11(4):2805-2825. doi: 10.1039/d0fo00216j. — View Citation

Rajha HN, Paule A, Aragones G, Barbosa M, Caddeo C, Debs E, Dinkova R, Eckert GP, Fontana A, Gebrayel P, Maroun RG, Napolitano A, Panzella L, Pasinetti GM, Stevens JF, Schieber A, Edeas M. Recent Advances in Research on Polyphenols: Effects on Microbiota, Metabolism, and Health. Mol Nutr Food Res. 2022 Jan;66(1):e2100670. doi: 10.1002/mnfr.202100670. Epub 2021 Dec 2. — View Citation

Todowede OO, Mianda SZ, Sartorius B. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa-a systematic review and meta-analysis. Syst Rev. 2019 Jan 3;8(1):4. doi: 10.1186/s13643-018-0927-y. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in Waist circumference (WC)	Reduction in WC	30 days
Other	Changes in Kg of body's fat mass	Improvement in fat mass (reduction)	30 days
Other	Changes in Body weight	reduction in body weight	30 days
Other	Changes in BMI	reduction in BMI	30 days
Primary	Changes in the concentrations of Triglycerides	A 10 mg/dL reduction in plasma triglycerides	30 days
Secondary	Changes in the concentrations of Total cholesterol	Reduction in plasma cholesterol	30 days
Secondary	Changes in the concentrations of LDL-c	Reduction in plasma LDL-c	30 days
Secondary	Changes in the concentration of HDL-c	increase in plasma HDL-c	30 days
Secondary	Changes in the concentrations of Fasting Blood Glucose (FBG)	Reduction in FBG	30 days
Secondary	Changes in Pulse wave velocity (m/s)	Measure of arterial stiffness (improvement in vascular function)	30 days
Secondary	Changes in mmHg of Blood pressure	Improvement in both systolic and diastolic blood pressure	30 days